We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CHGCY market cap is 83.3B. The company's latest EPS is JPY 117.7744 and P/E is 0.41.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 787.01B | 999.76B | 1.26T | 1.14T | 1.17T |
| Operating Income | 301.23B | 419.36B | 531.18B | 439.17B | 542B |
| Net Income | 214.73B | 303B | 374.43B | 325.47B | 387.32B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.24T | 1.54T | 1.87T | 1.93T | 2.21T |
| Total Liabilities | 255.5B | 350.68B | 445.37B | 306.97B | 306.87B |
| Total Equity | 980B | 1.19T | 1.42T | 1.63T | 1.9T |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 205.04B | 279.63B | 244.11B | 409.93B | 447.6B |
| Investing | -98.31B | -118.93B | -145.99B | -37.29B | -227.37B |
| Financing | -99.5B | -107.41B | -145.64B | -139.33B | -141.01B |
| Market Cap | 83.3B |
| Price to Earnings Ratio | 0.41 |
| Price to Sales Ratio | 0.14 |
| Price to Cash Ratio | 0.3 |
| Price to Book Ratio | 0.08 |
| Dividend Yield | 1.06% |
| Shares Outstanding | 3.29B |
| Average Volume (1 week) | 95.1k |
| Average Volume (1 Month) | 186.55k |
| 52 Week Change | 27.61% |
| 52 Week High | 27.19 |
| 52 Week Low | 14.52 |
| Spread (Intraday) | 0.29 (1.13%) |
| Company Name | Chugai Pharmaceutical Ltd (PK) |
| Address |
2-1-1 muromachi-nihonbashi chuo, tokyo 103-8324 |
| Website | https://www.chugai-pharm.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
